Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Gadolinium

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44363   clinical trials with a EudraCT protocol, of which   7387   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    275 result(s) found for: Gadolinium. Displaying page 1 of 14.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-004736-79 Sponsor Protocol Number: 1102-CT02 Start Date*: 2007-03-06
    Sponsor Name:Antisense Therapeutics Ltd.
    Full Title: A double-blind, placebo-controlled, randomised trial to prove the therapeutic concept and to determine the pharmacokinetic profile of ATL 1102 (VLA-4 antisense oligonucleotide) by subcutaneous inje...
    Medical condition: To evaluate the efficacy of a selected treatment regimen of ATL 1102 in patients with Relapsing Remitting MS (RRMS) inflammatory lesions using MRI with gadolinium administration compared to placebo.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2005-000677-21 Sponsor Protocol Number: CMC-P004 Start Date*: 2005-05-20
    Sponsor Name:CMC Contrast AB
    Full Title: Evaluation of the diagnostic quality of CMC-001 (manganese chloride tetrahydrate) in liver MR-imaging in patients with liver metastases in comparison to Gadolinium BOPTA. A randomised cross-over Ph...
    Medical condition: Liver metastases. CMC-001 is an orally administered contrast medium containing manganese (Mn) as the active imaging substance. Manganese is absorbed by the healthy parts of the liver and will thus ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001560-30 Sponsor Protocol Number: 20241 Start Date*: 2020-05-04
    Sponsor Name:Bayer AG
    Full Title: Multicenter, single-blind, adaptive dose finding study of single intravenous injections of BAY 1747846 with corresponding blinded read in adult participants with known or highly suspected CNS lesio...
    Medical condition: Central nervous system (CNS) pathology
    Disease: Version SOC Term Classification Code Term Level
    22.1 10022891 - Investigations 10029820 Nuclear magnetic resonance imaging gadolinium-enhanced LLT
    20.0 10029205 - Nervous system disorders 10051290 Central nervous system lesion PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-006205-25 Sponsor Protocol Number: 4118 Start Date*: 2008-11-06
    Sponsor Name:Hôpitaux Universitaires de Strasbourg
    Full Title: Suivi IRM de l’infiltration macrophagique chez des patients présentant une SEP traitée par Tysabri
    Medical condition: Sclérose en plaques (SEP)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-006724-35 Sponsor Protocol Number: fMRI-CA_2008 Start Date*: 2008-09-08
    Sponsor Name:CMIV
    Full Title: Functional MRI after administration of Gd-based blood pool contrast agents
    Medical condition: This study aims to investigate the possibility to obtain higher functional contrast and better spatial assessment in contrast enhanced functional Magnetic Resonance Imaging (fMRI) as compared to st...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029820 Nuclear magnetic resonance imaging gadolinium-enhanced LLT
    9.1 10029817 Nuclear magnetic resonance imaging brain LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-006135-29 Sponsor Protocol Number: PH-107 Start Date*: 2012-09-03
    Sponsor Name:Bracco Imaging S.p.A.
    Full Title: PHASE IV, DOUBLE-BLIND, MULTI-CENTER, RANDOMIZED, CROSSOVER STUDY TO COMPARE 0.1 mmol/kg OF PROHANCE® WITH 0.1 mmol/kg OF GADOVIST®/GADAVIST™ IN MAGNETIC RESONANCE IMAGING (MRI) OF THE BRAIN (TRUTH)
    Medical condition: Have confirmed or are highly suspected of brain disease likely to enhance as determined by the following: clinical/neurological symptomatology; diagnostic testing, such as CT or previous MRI exam...
    Disease: Version SOC Term Classification Code Term Level
    15.0 10022891 - Investigations 10029820 Nuclear magnetic resonance imaging gadolinium-enhanced LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-012318-33 Sponsor Protocol Number: 4498 Start Date*: 2009-08-26
    Sponsor Name:Hôpitaux Universitaires de Strasbourg
    Full Title: EVALUATION DE LA PRISE DE CONTRASTE APRES INJECTION DE VASOVIST DANS LES LESIONS INFLAMMATOIRES DE SCLEROSE EN PLAQUES
    Medical condition: Patients présentant une sclérose en plaques avec des lésions inflammatoires aigues rehaussées sur une première IRM réalisée avec un chélate de gadolinium standard.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000941-11 Sponsor Protocol Number: GMRA-102,Am.No.1 Start Date*: 2013-03-27
    Sponsor Name:Bracco Imaging S.p.A.
    Full Title: A PROSPECTIVE MULTICENTER COHORT STUDY EVALUATING THE LONG TERM RETENTION OF GADOLINIUM IN HUMAN BONE AND SKIN AFTER THE RETROSPECTIVE ADMINISTRATION OF MULTIHANCE® OR PROHANCE® IN COMPARISON WITH...
    Medical condition: Nephrogenic Systemic Fibrosis (NSF)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2006-001947-70 Sponsor Protocol Number: MBP8298-RR-01 Start Date*: 2006-09-14
    Sponsor Name:BioMS Technology Corp.
    Full Title: A Double Blind, Placebo Controlled Multi-Center Pilot Study to Evaluate the Efficacy and Safety of MBP8298 in Relapsing Remitting Multiple Sclerosis
    Medical condition: Relapsing Remitting Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-006338-32 Sponsor Protocol Number: WA21493 Start Date*: 2008-05-06
    Sponsor Name:Hoffman La Roche Ltd
    Full Title: Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 do...
    Medical condition: Relapsing remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) DE (Completed) ES (Completed) CZ (Completed) SK (Completed) DK (Completed) BE (Completed) NL (Completed) FI (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002455-26 Sponsor Protocol Number: IRON-CMR Start Date*: 2014-09-20
    Sponsor Name:Karolinska Institute
    Full Title: The use of intravenous Iron oxide as a contrast agent for cardiac magnetic resonance imaging.
    Medical condition: Cardiovascular diseases: Acute myocardial infarction, chronic myocardial infarction, myocardial ischemia, myocarditis, diffuse myocardial fibrosis.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001529-27 Sponsor Protocol Number: 20050401 Start Date*: 2005-06-13
    Sponsor Name:Jan Engvall
    Full Title: Effect of reperfusion on infarct size and cardiac function evaluated with MRI and echocardiography/Effekt av reperfusion på infarktstorlek och hjärtfunktion utvärderat med MR och ultraljud
    Medical condition: Patients recovering 6weeks after primary PCI for ST-elevation Myocardial Infarction. This application concerns the use of gadolinium contrast to visualise myocardial infarct size using MRI. Aden...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020775-22 Sponsor Protocol Number: IT2191002 Start Date*: 2010-08-10
    Sponsor Name:ClinTrio Ltd.
    Full Title: Assessment of myocardial viability using reduced doses of contrast agent (GV Via)
    Medical condition: Patients with a history of chronic myocardial infarction due to coronary artery disease and a successful LGE-CMR scan.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003086-40 Sponsor Protocol Number: PIX001 Start Date*: 2008-04-08
    Sponsor Name:Fondation Charcot Stichting
    Full Title: A Phase I/II Study of Pixantrone in Patients with an Aggressive Relapsing Remitting (RR) or Secondary Progressive (SP) Multiple Sclerosis (PIXAMS)
    Medical condition: aggressive relapsing remitting (RR) or secondary progressive (SP) multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001439-30 Sponsor Protocol Number: ALS-Gd64/001 Start Date*: 2013-03-22
    Sponsor Name:Navitas Life Sciences GmbH
    Full Title: Exploratory evaluation of the potential for long-term retention of Gadolinium in the bones of patients who have received Gadolinium based Contrast Agents according to their medical history.
    Medical condition: Retention of gadolinium/traces of metals/minerals to be determined in bone/skin specimens and evaluation of signs of nephrogenic systemic fibrosis in skin.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Prematurely Ended) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003886-33 Sponsor Protocol Number: MH-148 Start Date*: 2014-02-28
    Sponsor Name:Bracco Imaging S.p.A.
    Full Title: PHASE IV, DOUBLE-BLIND, MULTI-CENTER, RANDOMIZED, TWO-ARM CROSSOVER STUDY TO COMPARE 0.1 mmol/kg OF MULTIHANCE® WITH 0.1 mmol/kg OF DOTAREM® AND 0.05 mmol/kg OF MULTIHANCE® WITH 0.1 mmol/kg OF DOTA...
    Medical condition: Patients have confirmed or are highly suspected to have brain tumor(s) (primary or secondary), as determined by: • clinical/neurological symptomatology; • diagnostic testing, such as CT or previ...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004848 10029820 Nuclear magnetic resonance imaging gadolinium-enhanced LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2009-012716-40 Sponsor Protocol Number: CO-200-201 Start Date*: 2009-12-31
    Sponsor Name:Peptimmune Inc.
    Full Title: The Effect of the Dose of PI-2301 on Efficacy, Safety, and Tolerability, in Subjects with the Relapsing Remitting Form of Multiple Sclerosis: A Phase 2 Randomized, double-blind, four–arm, parallel,...
    Medical condition: Relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Prematurely Ended) CZ (Completed) DE (Completed) FR (Ongoing) PL (Prematurely Ended) SK (Completed) BG (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023003-96 Sponsor Protocol Number: BAY86-4875/91741 Start Date*: 2012-04-25
    Sponsor Name:Bayer HealthCare AG
    Full Title: Open-label, multicenter, pharmacokinetic, and safety study in children (term newborn infants to 23 months of age) undergoing a contrast-enhanced MRI with an intravenous injection of 0.1 mmol/kg BW ...
    Medical condition: Pediatric subjects aged <2 years (term newborn infants to toddlers 23 months of age inclusive) scheduled to undergo routine gadolinium-enhanced MRI of any body region
    Disease:
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001796-11 Sponsor Protocol Number: contrast 01/2007 Start Date*: 2008-01-30
    Sponsor Name:Institute for Diagnostic Radiology and Neuroradiology, Ernst-Moritz-Arndt University Greifswald
    Full Title:
    Medical condition: The following trial should be performed in patients with a stenosis of supraaortal and intracranial vessels, who are subjected to a plain cranial CT and CT angiography, which is considered to be a ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065141 Vascular diagnostic procedure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-000952-32 Sponsor Protocol Number: BAY86-4873/16078 Start Date*: 2015-09-24
    Sponsor Name:Bayer HealthCare AG
    Full Title: Open-label, multi-center study to evaluate the safety, efficacy, and plasma gadolinium concentrations after an intravenous injection of 0.1 mL/kg body weight Eovist/Primovist for enhanced magnetic ...
    Medical condition: Magnetic Resonance Imaging
    Disease: Version SOC Term Classification Code Term Level
    18.0 10022891 - Investigations 10072304 Nuclear magnetic resonance imaging liver PT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Nov 06 00:19:57 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA